UMIN-CTR Clinical Trial

Recruitment status Terminated
Unique ID issued by UMIN UMIN000015784
Receipt No. R000018369
Scientific Title Genome analysis on drug adverse reaction
Date of disclosure of the study information 2014/11/28
Last modified on 2021/08/26 (Ver. 3)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Genome analysis on drug adverse reaction
Acronym Genome analysis on drug adverse reaction
Scientific Title Genome analysis on drug adverse reaction
Scientific Title:Acronym Genome analysis on drug adverse reaction
Region
Japan

Condition
Condition Malignant diseases
Classification by specialty
Medicine in general Hematology and clinical oncology
Classification by malignancy Malignancy
Genomic information YES

Objectives
Narrative objectives1 To elucidate genetic basis of unreported/serious adverse effects by anti-neoplastic agents, genome (exome, whole genemo) analyses are performed.
Basic objectives2 Others
Basic objectives -Others Genome analyses
Trial characteristics_1 Exploratory
Trial characteristics_2 Others
Developmental phase Not applicable

Assessment
Primary outcomes Relationship between drug adverse reactions and genome information.
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Individuals experienced unreported/serious adverse reaction caused by anti-neoplastic agents.
Key exclusion criteria Not applicable
Target sample size 55

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Takiguchi, Yuichi
Organization Graduate School of Medicine, Chiba University
Division name Department of Medical Oncology
Zip code
Address 1-8-1, Inohana, Chuo-ku, Chiba
TEL 043-226-2806
Email takiguchi@faculty.chiba-u.jp

Public contact
Name of contact person
1st name
Middle name
Last name Takiguchi, Yuichi
Organization Graduate School of Medicine, Chiba University
Division name Department of Medical Oncology
Zip code
Address 1-8-1, Inohana, Chuo-ku, Chiba
TEL 043-226-2806
Homepage URL
Email takiguchi@faculty.chiba-u.jp

Sponsor
Institute Department of Medical Oncology
Graduate School of Medicine, Chiba University
Institute
Department

Funding Source
Organization Ministry of Health, Labour and Welfare
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor Department of Genome Biology, Kinki University School of Medicine
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 千葉大学大学院医学研究院(千葉県)

Other administrative information
Date of disclosure of the study information
2014 Year 11 Month 28 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Terminated
Date of protocol fixation
2013 Year 05 Month 24 Day
Date of IRB
2013 Year 05 Month 28 Day
Anticipated trial start date
2013 Year 05 Month 30 Day
Last follow-up date
2020 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
2020 Year 03 Month 31 Day

Other
Other related information Analyses are performed by individual case upon occurrence of unreported/serious drug adverse reaction.

Management information
Registered date
2014 Year 11 Month 28 Day
Last modified on
2021 Year 08 Month 26 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018369